clinical trial · NCT04223193
Flexible-Dose Trial in Early Parkinson's Disease (PD)
AbbVie·phase3·completed·n = 304
Parkinson DiseaseTavapadonPlacebo
brief summary
The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
started
Jan 6, 2020
primary completion
Oct 1, 2024
completion
Oct 1, 2024
last updated
Nov 21, 2025
official title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol